Literature DB >> 2416885

A preliminary trial of poly(I,C)-LC in multiple sclerosis.

D E McFarlin, C T Bever, A M Salazar, H B Levy.   

Abstract

An open Phase I trial of poly(I,C)-LC in multiple sclerosis was conducted. Serious temperature elevations were typical and associated with transient accentuation of neurological dysfunction which required intensive nursing care, but no permanent complications to the treatment were observed. A regimen was developed for management of the side effects and reducing patient discomfort. Although there was a suggestion of stabilization of the disease in some patients, a conclusion about efficacy cannot be reached without a controlled trial. Future use of poly(I,C)-LC in multiple sclerosis should be confined to experimental trials in a research setting.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2416885

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN： 0732-6580


  11 in total

Review 1.  Influenza, immune system, and pregnancy.

Authors:  Renju S Raj; Elizabeth A Bonney; Mark Phillippe
Journal:  Reprod Sci       Date:  2014-06-04       Impact factor: 3.060

Review 2.  TLR-based immune adjuvants.

Authors:  Folkert Steinhagen; Takeshi Kinjo; Christian Bode; Dennis M Klinman
Journal:  Vaccine       Date:  2010-08-14       Impact factor: 3.641

3.  Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.

Authors:  M Kende; H W Lupton; W L Rill; P Gibbs; H B Levy; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

4.  Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice.

Authors:  J P Wong; E G Saravolac; D Sabuda; H B Levy; M Kende
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

5.  Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.

Authors:  M Kende; H W Lupton; W L Rill; H B Levy; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 6.  Toll-like receptors: the swiss army knife of immunity and vaccine development.

Authors:  Jennifer K Dowling; Ashley Mansell
Journal:  Clin Transl Immunology       Date:  2016-05-20

Review 7.  Innate immune responses in the CNS: role of toll-like receptors, mechanisms, and therapeutic opportunities in multiple sclerosis.

Authors:  Giulio Podda; Mukanthu Nyirenda; James Crooks; Bruno Gran
Journal:  J Neuroimmune Pharmacol       Date:  2013-06-28       Impact factor: 7.285

8.  Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.

Authors:  Christiane Stahl-Hennig; Martin Eisenblätter; Edith Jasny; Tamara Rzehak; Klara Tenner-Racz; Christine Trumpfheller; Andres M Salazar; Klaus Uberla; Karen Nieto; Jürgen Kleinschmidt; Reiner Schulte; Lutz Gissmann; Martin Müller; Anna Sacher; Paul Racz; Ralph M Steinman; Mariagrazia Uguccioni; Ralf Ignatius
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

9.  Broad-spectrum drugs against viral agents.

Authors:  Mary E Christopher; Jonathan P Wong
Journal:  Int J Mol Sci       Date:  2008-09-01       Impact factor: 6.208

10.  TLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin Repair.

Authors:  Chandramohan Natarajan; Song-Yi Yao; Subramaniam Sriram
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.